Evidence mapPaperPMID 34298829Full record

ReviewCancers2021

Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere.

Dean G Campelj, Craig A Goodman, Emma Rybalka

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Involvement of the gut microbiota in cancer cachexia.American journal of physiology. Cell physiology · 2024
    Review
  18. Article
  19. Drug-related sarcopenia as a secondary sarcopenia.Geriatrics & gerontology international · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Dean G CampeljInstitute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.
Craig A GoodmanInherited and Acquired Myopathy Program, Australian Institute for Musculoskeletal Science (AIMSS), Victoria University, St Albans, VIC 3021, Australia.ORCID 0000-0002-5874-7743
Emma RybalkaInstitute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.ORCID 0000-0002-4854-0036
The University of Melbourne · AUAustralian Institute for Musculoskeletal Science · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cachexia is a debilitating multi-factorial wasting syndrome characterised by severe skeletal muscle wasting and dysfunction (i.e., myopathy). In the oncology setting, cachexia arises from synergistic insults from both cancer-host interactions and chemotherapy-related toxicity. The majority of studies have surrounded the cancer-host interaction side of cancer cachexia, often overlooking the capability of chemotherapy to induce cachectic myopathy. Accumulating evidence in experimental models of cachexia suggests that some chemotherapeutic agents rapidly induce cachectic myopathy, although the underlying mechanisms responsible vary between agents. Importantly, we highlight the capacity of specific chemotherapeutic agents to induce cachectic myopathy, as not all chemotherapies have been evaluated for cachexia-inducing properties-alone or in clinically compatible regimens. Furthermore, we discuss the experimental evidence surrounding therapeutic strategies that have been evaluated in chemotherapy-induced cachexia models, with particular focus on exercise interventions and adjuvant therapeutic candidates targeted at the mitochondria.

Indexed as

cachexiachemotherapyexercise therapymitoprotectionmuscle wastingmyopathypharmaceutical adjuvantsskeletal muscle

Identifiers

PMID34298829
PMCPMC8304349
OpenAlexW3186651758

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.